TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: peritoneal clearance of high molecular weight solutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Improvements in TCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance to treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adenoma detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Reduction in antibiotic prescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent predicted resting energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' satisfaction rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Median pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum pain ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TOTPAR6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: geometric mean concentrations of antibodies against hepatitis A and B antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentages of subjects achieving hSBA titers ≥8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentages of subjects reporting adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: medical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active cervical range of motion (ROM) into rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement time in direction congruent conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement time in direction incongruent conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer heavy drinking days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in median number of drinks consumed per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in percentage of patients reporting heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: worst cleansing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in mean paediatric Crohn's disease activity index (PCDAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any hypoglycemia events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EDITS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual self-confidence score (SSCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Progression of visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean VL log(10) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient empowerment in managing condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient knowledge about medications
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean decrease in haemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline in the Positive and Negative Syndrome Scale total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise tolerance (6 MWT distance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systolic function (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: C-reactive protein (CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of days with ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to participate in treatment decisions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Axial length (AL) growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of IFG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Risk of IGT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Montgomery Asberg Depression Rating Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: physician global assessments of menopause scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with the prescribed eating pattern
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean score for tumor location assignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accuracy of surgical resection proposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time spent on assessing tumor location
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average additional sleep duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Reduced symptoms of sleepiness, anger, vigor, fatigue, and confusion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: ORR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conditions for insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain relief measured by VNRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiologically confirmed response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall OKS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient satisfaction with postoperative pain management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: quality of recovery scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to readiness for surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental cost-effectiveness ratio per quality-adjusted life-year gained
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Non-inferiority of MT to AT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMAO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: aortic relative vascular enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aorta-to-inferior vena cava (IVC) CNR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IVC-to-aorta venous-to-arterial enhancement ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: early postpartum contraceptive uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: contraceptive continuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity and intensity of symptoms (Kuppermann index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Follicular stimulating hormone (FSH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Luteinizing hormone (LH) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: DINDs occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: radiographic vasospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of women remaining disease-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to clinical recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving >/=30% reduction in mean IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of multiple organ dysfunction syndrome (MODS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of mechanical ventilation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sagittal plane range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median urinary free cortisol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Response rate after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in nonspine fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Patients free of bleeding at 1 and 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidelity of the delivery of the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-RNA <50cps/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: chronic sleep reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGIC response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: assessments of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: apparent clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent volume of distribution (V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic anti-Xa levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma prothrombin fragments 1+2 (F(1+2)) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thrombin generation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: theory of mind
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sREM achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sLDA achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in physical functioning (HAQ-DI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive attitudes toward evidence-based practice (EBP)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of ipsilateral neurologic events (stroke and transient ischemic attack)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Medication nonadherence reasons identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TAT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean left ventricular fractional shortening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postprandial symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: CD4 T-cell responses to vaccines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lives saved
Endpoint domain: Mortality/survival
Primary endpoint: Bladder capacity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ethanol elimination from blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: haemodynamic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of postoperative recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: knowledge retention on 3-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: comfort in managing menopause
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: C50 values for no response to calling the person by name
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C50 values for tolerance to shake and shout
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C50 values for tolerance to tetanic stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cosmetic scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Body image scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: in-hospital case fatality rate (CFR)
Endpoint domain: Mortality/survival
Primary endpoint: complete recovery rate among survivors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of relapses or recurrences
Endpoint domain: Adverse events/effects
Primary endpoint: weighted mean glucose AUC(0‐4 hours)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Goal completion
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Metoclopramide administration frequency for PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: noncompliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discharge summary quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of sun protection measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Perception of advantages of sun protection methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of patients with radiographic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of joint space narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation in the basal ganglia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Plasma concentrations of IL-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Atenolol-induced glucose change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tooth shade improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating RBC volume/mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Weekly hematocrit (Hct) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for phototherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of no-reflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of additional reperfusion therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of perioperative bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of no-reflow/slow flow
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of major adverse cardiac events (MACE) within 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Geometric mean concentrations of anti-PhtD IgG and anti-PcpA IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TREM(r) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: area under the HBV DNA curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in A1c from baseline to endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Two-hour post-prandial BG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to sense a change in lumbar position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lactic acidosis threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak work load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative feelings of satiety and fullness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of major response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained increases in hemoglobin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in PPT around the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction in localized hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28 (CRP) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function improvement (HAQ-DI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UCNVA and UCDVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Contrast sensitivity at 18 CPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saturation of oxygen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Behaviour on coming out of anaesthesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bioequivalence of FS Spiromax and Seretide Accuhaler
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PYY(3‐36) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: level of reduction on burning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary calcium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NGAL levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of upper respiratory tract infections
Endpoint domain: Adverse events/effects
Primary endpoint: risk of respiratory tract infections lasting longer than 3 days
Endpoint domain: Adverse events/effects
Primary endpoint: number of days with respiratory symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: number of incontinent episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety and tolerability of seletalisib
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile of seletalisib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamic effects on psoriatic biology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Responsiveness of leg alignment reactions to sham adjustment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of anterior rotation of the fetal head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of PAI-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Continuous use of diaphragm pacing system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to be removed from mechanical ventilation for more than 4 hours per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-benefit of diagnostic tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response rate for complicated grief treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to response for complicated grief treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gastritis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: accuracy of treatment planning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum lutein concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent indoor walking ability performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning